Page 198 - Let them speak Towards a patient reported outcome measure set for

Chapter 7
References
1. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual
disability: a meta-analysis of population-based studies. Research in developmental disabilities.
2011;32(2):419–36.
2. Harris JC. Intellectual disability: Understanding its development, causes, classification,
evaluation, and treatment: Oxford University Press; 2006.
3. Wang J, Wang Y, Wang L, Chen WY, Sheng M. The diagnostic yield of intellectual disability:
combined whole genome low-coverage sequencing and medical exome sequencing. BMC
medical genomics. 2020;13:1–15.
4. Edwards G, Jones C, Pearson E, Royston R, Oliver C, Tarver J, et al. Prevalence of anxiety
symptomatology and diagnosis in syndromic intellectual disability: A systematic review and
meta-analysis. Neuroscience & Biobehavioral Reviews. 2022;138:104719.
5. Borland R, Hu N, Tonge B, Einfeld S, Gray K. Participation in sport and physical activity in adults
with intellectual disabilities. Journal of Intellectual Disability Research. 2020;64(12):908–22.
6. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common
sense to hard science. BMC medicine. 2011;9(1):1–12.
7. Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LE, et al. Patient‐reported
outcome measures (PROMs): A review of generic and condition‐specific measures and a
discussion of trends and issues. Health Expectations. 2021.
8. Gibbons C, Porter I, Goncalves-Bradley DC, Stoilov S, Ricci-Cabello I, Tsangaris E, et al. Routine
provision of feedback from patient-reported outcome measurements to healthcare providers
and patients in clinical practice. Cochrane Database Syst Rev. 2021;10:CD011589.
9. Health USDo, Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE,
Research, et al. Guidance for industry: patient-reported outcome measures: use in medical
product development to support labeling claims: draft guidance. Health and Quality of Life
Outcomes. 2006;4(1):79.
10. Djukic A, Holtzer R, Shinnar S, Muzumdar H, Rose SA, Mowrey W, et al. Pharmacologic
treatment of Rett syndrome with glatiramer acetate. Pediatric neurology. 2016;61:51–7.
11. Müller AR, Luijten MA, Haverman L, de Ranitz-Greven WL, Janssens P, Rietman AB, et al.
Understanding the impact of tuberous sclerosis complex: development and validation of the
TSC-PROM. BMC medicine. 2023;21(1):1–15.
12. Müller AR, van Silfhout NY, den Hollander B, Kampman DH, Bakkum L, Brands MM, et al.
Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials
in genetic neurodevelopmental disorders and intellectual disability. Therapeutic Advances in
Rare Disease. 2024;5:26330040241245721.
13. Greenberg KK, Schwartz AE, Kramer JM. Adoption of patient‐reported outcome measures
with youth with intellectual/developmental disabilities: Contextual influences and practice
patterns. Child: Care, Health and Development. 2021;47(4):501–8.
14. Kang S, Jones A, Shaffer RC, Erickson CA, Schmitt LM. Developing improved outcome
measures in FXS: Key stakeholder feedback. Research in developmental disabilities.
2023;137:104502.
15. Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported
outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR
COA emerging good practices task force report. Value in Health. 2017;20(7):838–55.
16. Maguire S, Davison J, McLaughlin M, Simms V, Bunting B. Exploring the psychometric properties
of self‐report instruments used to measure health‐related quality of life and subjective
wellbeing of adolescents with intellectual disabilities: A Consensus‐based Standards for
the Selection of Health Measurement Instruments (COSMIN) systematic review. Journal of
Applied Research in Intellectual Disabilities. 2023;36(5):899–915.
17. Intro to PROMIS [Available from: https://www.healthmeasures.net/explore-measurement-
systems/promis/intro-to-promis.
196